Sanofi's Rare Lung Disease Drug Outperforms Standard Therapy in Head-to-Head Trial Written By sheeba farhat19 May 2026 9:58 PM ISTLondon: French drugmaker Sanofi said on Monday a trial showed its rare disease therapy was better than standard care in raising levels of a ‌key...
Sanofi Pulls Diabetes Drug Tzield from USFDA Fast-Track Review Amid Safety Concerns: Report Written By sheeba farhat7 May 2026 10:53 PM ISTBengaluru: Sanofi has asked the U.S. Food and Drug Administration to ​pull its diabetes drug ​out of the regulator's new fast-track review program,...
FDA Expands Teplizumab Approval to Infants for Delaying Type 1 Diabetes Written By Dr. Kamal Kant Kohli28 April 2026 9:00 AM ISTThe U.S. Food and Drug Administration has broadened approval of Teplizumab-developed by Sanofi-to include children as young as 1 year old, enabling...
FDA extends approval of Dupilumab for Young Children with Chronic Spontaneous Urticaria Written By Dr. Kamal Kant Kohli24 April 2026 9:15 PM ISTThe FDA has expanded approval of dupilumab to include children aged 2 to 11 years with chronic spontaneous urticaria who continue to have symptoms...
Roche Submits Fenebrutinib for MS Approval, Reports Improved Relapse Control Amid Death Cases Written By sheeba farhat22 April 2026 10:00 AM ISTNew Delhi: Swiss drugmaker Roche on Wednesday said it was submitting its experimental multiple sclerosis drug fenebrutinib to global regulators after...
Sanofi's Sarclisa Gets EMA Nod for Subcutaneous On-Body Injector Version Written By sheeba farhat29 March 2026 10:30 AM ISTBengaluru: French drugmaker Sanofi said on Friday ​the European ​Medicines Agency has recommended the approval of ​a subcutaneous version of its blood...
Sanofi Replaces CEO Paul Hudson Amid Vaccine Headwinds, Names Belen Garijo Successor Written By sheeba farhat13 Feb 2026 2:00 PM ISTNew Delhi: French drugmaker Sanofi abruptly ousted its CEO Paul Hudson on Thursday, underscoring rising pressure from U.S. vaccine headwinds and a...
Amlitelimab Shows Promise in Moderate-to-Severe Atopic Dermatitis in Phase 3 trial Written By Dr. Kamal Kant Kohli24 Jan 2026 8:00 AM ISTAmlitelimab, an OX40 ligand-targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, demonstrated clinical...
USFDA Halts Fast-Track Reviews of Disc, Sanofi Drugs Over Safety, Death Concerns Written By sheeba farhat16 Jan 2026 9:02 PM ISTThey also stalled their review of French drugmaker Sanofi's Tzield for late-stage type 1 diabetes by more than a month over adverse event reports,...
UP Drug Dept Probes Rs 72 Cr Fake Medicine Racket, Team Sent to Puducherry to Trace Supply Chain Written By Parthika Patel26 Dec 2025 8:47 PM ISTAgra: With the investigation into a large-scale fake medicine racket entering a crucial phase, the Agra unit of the Uttar Pradesh Drug Department has...
Sanofi to acquire vaccine maker Dynavax for USD 2.2 billion Written By Ruchika Sharma24 Dec 2025 3:30 PM ISTParis: Sanofi has announced that it has entered into an agreement to acquire Dynavax Technologies Corporation, a publicly traded vaccines company...
Sanofi-Regeneron Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Written By Ruchika Sharma23 Dec 2025 11:30 AM ISTParis: Sanofi and Regeneron have announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing...
